Lysopadol Mint 20 mg Lozenges

  • Name:

    Lysopadol Mint 20 mg Lozenges

  • Company:
    info
  • Active Ingredients:

    Ambroxol hydrochloride

  • Legal Category:

    Supply through pharmacy only

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 10/07/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 8/7/2019

Click on this link to Download PDF directly

SANOFI

SANOFI

Company Products

Medicine NameActive Ingredients
Medicine Name Adenocor Active Ingredients Adenosine
Medicine Name Amaryl 1mg Tablets Active Ingredients Glimepiride
Medicine Name Amaryl 3mg Tablets Active Ingredients Glimepiride
Medicine Name Anthisan Cream Active Ingredients Mepyramine Maleate
Medicine Name Apidra 100 units/ml solution for injection in a cartridge Active Ingredients Insulin Glulisine
Medicine Name Apidra 100 Units/ml solution for injection in a vial Active Ingredients Insulin Glulisine
Medicine Name Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen Active Ingredients Insulin Glulisine
Medicine Name Aprovel 150mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 300mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 75mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Arava 10 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arava 20 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Bisolvon Oral Solution Active Ingredients Bromhexine hydrochloride
Medicine Name Brolene 0.1%w/v Eye Drops Solution Active Ingredients Propamidine Isethionate
Medicine Name Brolene 0.15% w/w Eye Ointment Active Ingredients Dibromopropamidine Isethionate
Medicine Name Buscopan 10 mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Ampoules Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Rx 10mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Calcium Resonium Active Ingredients Calcium polystyrene sulfonate
Medicine Name Cerubidin 20mg Powder for Solution for Injection Active Ingredients daunorubicin hydrochloride
Medicine Name Cidomycin Paediatric 20mg/2ml Solution For Injection Active Ingredients Gentamicin sulfate
Medicine Name Claforan Powder for Solution for Injection 1g Active Ingredients Cefotaxime sodium
Medicine Name Claforan Powder for Solution for Injection 500mg Active Ingredients Cefotaxime sodium
Medicine Name Clexane 10,000 IU (100mg)/1ml Solution for Injection Active Ingredients Enoxaparin sodium
Medicine Name Clexane 2,000 IU (20 mg) /0.2 mL Solution for Injection Active Ingredients Enoxaparin sodium
1 - 0 of 176 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 8 July 2019 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Supply through pharmacy only

Updated on 10 July 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 6 July 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 7 - Marketing authorisation holder

The marketing authorisation holder has been updated to sanofi-aventis Ltd, T/A SANOFI, Citywest Business Campus, Dublin 24, Ireland.

Section 8 - Marketing Authorisation Numbers

The marketing authorisation number has been updated from PA 7/63/1 to PA 540/186/1

Section 10 - Date of revision of the text

The date has been revised to June 2018

Updated on 13 May 2016 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 2 Qualitative and Quantitative Composition

New text of “with known effect” has been added to the second paragraph of this section.

 

The word “the” has replaced the word “a” in the third paragraph of this section.

 

Section 4.2 Posology and Method of Administration

Sub-headings of “Posology” and “Paediatric population” have been added to this section.

 

A new sub-heading of “Method of administration”, together with corresponding text, has been added to this section.

 

Section 4.3 Contraindications

The previous first sentence of this section “Lysopadol Mint 20 mg Lozenges should not be used in patients known to be hypersensitive to ambroxol or any of the excipients” has been replaced with “Hypersensitivity to the active substance or to any of the excipients listed in section 6.1”.

 

Section 4.4 Special Warnings and Precautions for Use

The previous text of:

 

“Lysopadol Mint 20 mg Lozenges should not be used in children under 12 years of age.

 

There have been very few reports of severe skin lesions such as Stevens-Johnson Syndrome and toxic epidermal necrolysis (TEN) in temporal association with the administration of expectorants such as ambroxol hydrochloride. Mostly these could be explained by the severity of the patient’s underlying disease and/or concomitant medication.

 

In addition during the early phase of a Stevens-Johnson Syndrome or TEN a patient may first experience non-specific influenza-like prodromes like e.g. fever, aching body, rhinitis, cough and sore throat. Misled by these non-specific influenza-like prodromes it is possible that a symptomatic treatment is started with a cough and cold medication. Therefore if new skin or       mucosal lesions occur, medical advice should be sought immediately and treatment with ambroxol hydrochloride discontinued as a precaution.”

 

has been replaced with the text:

 

“There have been reports of severe skin reactions such as erythema multiforme, Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and acute generalised exanthematous pustulosis (AGEP) associated with the administration of ambroxol hydrochloride. If symptoms or signs of a progressive skin rash (sometimes associated with blisters or mucosal lesions) are present, ambroxol hydrochloride treatment should be discontinued immediately and medical advice should be sought.”

 

A new sub-heading of “Paediatric population”, together with corresponding text, has been added at the end of this section.

 

Section 4.6 Fertility, Pregnancy and Lactation

The “Fertility” sub-heading and corresponding text have now moved from being the first paragraph to being the final paragraph of this section.

 

A new sub-heading of “Breastfeeding” has replaced the previous sub-heading of “Lactation” in this section.

 

Section 4.8 Undesirable Effects

The frequency estimate details have been updated from:

 

“Very common: ≥ 10 %

Common: ≥ 1 % and < 10 %

Uncommon: ≥ 0.1 % and < 1 %

Rare: ≥ 0.01 % and < 0.1 %

Very rare: < 0.01 %

Not known: cannot be estimated from the available data.”

 

to:

 

“Very common (≥ 1/10)

Common (≥ 1/100 and < 1/10)

Uncommon (≥ 1/1,000 and < 1/100)

Rare (≥ 1/10,000 and < 1/1,000)

Very rare (< 1/10,000)

Not known (cannot be estimated from the available data).”

 

The text “, skin and subcutaneous tissue disorders” has been deleted from the “Immune system disorders” sub-heading.

 

The text “Rare: hypersensitivity reactions” has been added to the Immune system disorders sub-heading details.

 

The text “rash, urticaria” and “and other hypersensitivity” has been deleted from the Immune system disorders sub-heading details.  The text now reads “Not known: anaphylactic reactions including anaphylactic shock, angioedema, and pruritus”.

 

A new sub-heading “Skin and subcutaneous tissue disorders”, together with corresponding text, has been added to this section.

 

Section 5.2 Pharmacokinetic Properties

The sub-heading of “Metabolism and elimination” has been amended to “Biotransformation and elimination”.

 

Section 5.3 Preclinical Safety Data

The word “revealed” in the first sentence of this section has been amended to “reveal”.

 

Section 9 Date of First Authorisation/Renewal of the Authorisation

The word “last” has been replaced with the word “latest” in this section.

 

Section 10 Date of Revision of the Text

The date has been updated from May 2015 to May 2016.

Updated on 13 May 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 9 May 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 9 May 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to further information section
  • Change to date of revision
  • Change of special precautions for disposal

Updated on 4 June 2015 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.6 Fertility, Pregnancy and Lactation
The word 'Animal' has been replaced with 'Nonclinical' in the Fertility paragraph of this section.

The word 'Animal' has been replaced with 'Nonclinical' in the second sentence of the Pregnancy paragraph of this section.

Section 4.7 Effects on Ability to Drive and Use Machines
The text 'from post-marketing data' has been added to this section.

Section 4.8 Undesirable Effects
New text after ‘Not known: cannot be estimated from the available data’ in the Frequency estimate details has been added to this section, before the list of disorders.

 

The frequency of the side effect ‘Dry throat’ has changed from ‘Not known’ to ‘Rare’ in the Gastrointestinal disorders and respiratory, mediastinal and thoracic disorders sub-heading of this section.

 

A new final paragraph regarding the reporting of suspected adverse reactions has been added to this section.

 

Section 5.1 Pharmacodynamic Properties

The figures ‘05’ have been added to the ATC code details in this section.

 

Section 5.2 Pharmacokinetic Properties

The text ‘non-delayed’ has been replaced with ‘immediate release’ in the first sentence of the Absorption paragraph of this section.

 

The figure ‘3’ has been added to ‘8%’ in the final sentence of the fifth paragraph of this section i.e. to now read ‘Total clearance is in the range of 660 mL/min, with renal clearance accounting for approximately 83% of the total clearance’.

 

Section 10 Date of Revision of the Text

The date has been updated from July 2014 to May 2015.

Updated on 29 May 2015 PIL

Reasons for updating

  • Change to further information section
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Correction of spelling/typing errors

Updated on 31 July 2014 SmPC

Reasons for updating

  • Change to product name
  • Change to section 1 - Name of medicinal product
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text
  • Introduction of new pack/pack size

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company


 The product name has changed from Lysopadol 20 mg Lozenges to Lysopadol Mint 20 mg Lozenges throughout the SPC.

Additional pack sizes of 18, 27, 36 and 45 have been added to section 6.5 (Nature and contents of container)

The revision date has been amended to July 2014 to reflect the approval date of the SPC by the HPRA

Updated on 25 July 2014 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to date of revision
  • Introduction of new pack/pack size

Updated on 27 May 2014 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 14 October 2011 SmPC

Reasons for updating

  • New SPC for new product
  • New SPC for medicines.ie

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

None provided